The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:1
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [1] The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors: Results from phase 3 of the RAISE project
    Pavel, M.
    Dromain, C.
    Ronot, M.
    Schaefer, N.
    Mandair, D.
    Gueguen, D.
    Elvira, D.
    Balazard, F.
    Dehaene, O.
    Schutte, K.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 126 - 126
  • [2] Endocan Expression Is Correlated with Poor Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors
    Lin, L. Y.
    Yeh, Y. C.
    Chu, C. H.
    Chen, M.
    NEUROENDOCRINOLOGY, 2018, 106 : 33 - 33
  • [3] Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors
    Lin, Liang-Yu
    Yeh, Yi-Chen
    Chu, Chia-Huei
    Won, Justin G. S.
    Shyr, Yi-Ming
    Chao, Yee
    Li, Chung-Pin
    Wang, Shin-E
    Chen, Ming-Huang
    MEDICINE, 2017, 96 (41)
  • [4] Relationship Between Lanreotide Autogel, Chromogranin A and Progression-Free Survival in Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Buil-Bruna, Nuia
    Dehez, Marion
    Manon, Amandine
    Thi Xuan Quyen Nguyen
    Troconiz, Inaki F.
    PANCREAS, 2016, 45 (03) : 472 - 473
  • [5] Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
    Pusceddu, Sara
    Vernieri, Claudio
    Di Maio, Massimo
    Marconcini, Riccardo
    Spada, Francesca
    Massironi, Sara
    Ibrahim, Toni
    Brizzi, Maria Pia
    Campana, Davide
    Faggiano, Antongiulio
    Giuffrida, Dario
    Rinzivillo, Maria
    Cingarlini, Sara
    Aroldi, Francesca
    Antonuzzo, Lorenzo
    Berardi, Rossana
    Catena, Laura
    De Divitiis, Chiara
    Ermacora, Paola
    Perfetti, Vittorio
    Fontana, Annalisa
    Razzore, Paola
    Carnaghi, Carlo
    Davi, Maria Vittoria
    Cauchi, Carolina
    Duro, Marilina
    Ricci, Sergio
    Fazio, Nicola
    Cavalcoli, Federica
    Bongiovanni, Alberto
    La Salvia, Anna
    Brighi, Nicole
    Colao, Annamaria
    Puliafito, Ivana
    Panzuto, Francesco
    Ortolani, Silvia
    Zaniboni, Alberto
    Di Costanzo, Francesco
    Torniai, Mariangela
    Bajetta, Emilio
    Tafuto, Salvatore
    Garattini, Silvio Ken
    Femia, Daniela
    Prinzi, Natalie
    Concas, Laura
    Lo Russo, Giuseppe
    Milione, Massimo
    Giacomelli, Luca
    Buzzoni, Roberto
    Delle Fave, Gianfranco
    GASTROENTEROLOGY, 2018, 155 (02) : 479 - +
  • [6] Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors
    Ming-Huang Chen
    Yi-Chen Yeh
    Yi-Ming Shyr
    Yi-Hua Jan
    Yee Chao
    Chung-Pin Li
    Shin-E Wang
    Cheng-Hwai Tzeng
    Peter Mu-Hsin Chang
    Chun-Yu Liu
    Ming-Han Chen
    Michael Hsiao
    Chi-Ying F. Huang
    Journal of Gastroenterology, 2013, 48 : 101 - 108
  • [7] Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors
    Chen, Ming-Huang
    Yeh, Yi-Chen
    Shyr, Yi-Ming
    Jan, Yi-Hua
    Chao, Yee
    Li, Chung-Pin
    Wang, Shin-E
    Tzeng, Cheng-Hwai
    Chang, Peter Mu-Hsin
    Liu, Chun-Yu
    Chen, Ming-Han
    Hsiao, Michael
    Huang, Chi-Ying F.
    JOURNAL OF GASTROENTEROLOGY, 2013, 48 (01) : 101 - 108
  • [8] Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
    Runsheng Chang
    Shouliang Qi
    Yanan Wu
    Yong Yue
    Xiaoye Zhang
    Wei Qian
    Cancer Imaging, 23
  • [9] Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
    Chang, Runsheng
    Qi, Shouliang
    Wu, Yanan
    Yue, Yong
    Zhang, Xiaoye
    Qian, Wei
    CANCER IMAGING, 2023, 23 (01)
  • [10] Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Lamarca, A.
    Barriuso, J.
    Castano, A.
    Hernando, J.
    Lopez, C.
    Marazuela, M.
    Crespo, G.
    Escudero, P.
    Capdevila, J.
    Garcia Carbonero, R.
    NEUROENDOCRINOLOGY, 2020, 110 : 230 - 230